Clinical trial
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly…
NCT00111787 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00111787 |
|---|---|
| Title | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer |
| Official title | A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Lapatinib, Paclitaxel |
| Enrollment | 49 |
| Start date | Apr 11, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | May 26, 2005 |
| Last update posted | May 31, 2017 |
| Countries | Australia, Canada, France, Israel, New Zealand, Spain, Tunisia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: